CJC-1295 vs SS-31
Side-by-Side Comparison
| Attribute | Cjc 1295 | Ss 31 |
|---|---|---|
| Category | Growth Hormone Secretagogue | Metabolic / Mitochondrial |
| Mechanism | CJC-1295 binds to GHRH receptors (GHRHR) on pituitary somatotroph cells, activating intracellular cAMP signaling to stimulate both the transcription of the GH gene and pulsatile release of endogenous... | SS-31 is a cell-permeable peptide with an alternating aromatic-cationic motif (D-Arg-Dmt-Lys-Phe-NH2) that allows it to cross membranes without a carrier. |
| Evidence Rating | D — Preclinical | A — FDA Approved |
| Clinical Status | Research-only / Not approved for human use | FDA-approved (Forzinity, September 2025) for Barth syndrome. Phase II (heart failure, renal dysfunction, age-related macular degeneration). |
| Safety Profile | Common: transient flushing/"head rush" within 5-10 minutes post-injection — hallmark of a potent injection, harmless and brief; Self-reported: flu-like symptoms, headaches, irritability, anxiety, nausea, hives (mild and transient) | Generally well-tolerated in clinical trials at tested doses; Common: injection site reactions (pain, redness) |
| Route | Subcutaneous | Subcutaneous |
| Dose Range | No DAC: 100 mcg before bed daily; DAC: 1–2 mg 2–3x weekly | 5–40 mg/day SC (Phase I tested 0.01–0.25 mg/kg); research protocols typically 10–50 mg |
| Frequency | Once daily (no DAC) or 2–3 times weekly (with DAC) | Once daily |
| Molecular Weight | No DAC: ~3367.9 g/mol; With DAC: ~3647.3 g/mol | ~639.8 g/mol |
| Half-Life | No DAC (mod GRF 1-29): ~30 min; With DAC: ~8 days | ~4 hours |
Overview
CJC-1295 and SS-31 are both research peptides studied across multiple applications. This comparison examines their mechanisms, evidence base, dosing protocols, and safety profiles to help researchers understand the key differences and overlaps.
CJC-1295 — Mechanism & Evidence
CJC-1295 is a synthetic analogue of growth hormone-releasing hormone (GHRH) originally developed by ConjuChem Technologies for HIV-associated lipodystrophy. It exists in two forms: with DAC (Drug Affinity Complex) for extended half-life of 5.8-8.1 days, and without DAC (Mod GRF 1-29) for shorter, pulsatile release with a half-life of approximately 30 minutes. Two 2006 randomized, placebo-controlled, double-blind clinical trials (Teichman et al.) demonstrated dose-dependent GH increases of 2-10 fold and IGF-1 increases of 1.5-3 fold in healthy adults aged 21-61. The No DAC version is generally considered the safer choice due to its physiological pulsatile pattern.
Key claims: Increases growth hormone and IGF-1; Improves body composition; Promotes deep sleep.
SS-31 — Mechanism & Evidence
SS-31 (Elamipretide) is a mitochondria-targeted tetrapeptide that selectively concentrates in the inner mitochondrial membrane, binding to cardiolipin and stabilizing cristae structure. It is being developed by Stealth BioTherapeutics for mitochondrial diseases, heart failure, and age-related mitochondrial dysfunction. It has undergone multiple Phase I–III clinical trials, including the TAZPOWER trial for Barth syndrome.
Key claims: Improves mitochondrial function; Reduces cardiac dysfunction; Potential anti-aging effects.
Shared Research Applications
Both peptides are studied for: Anti-Aging.
CJC-1295 is also researched for: Body Composition.
SS-31 is also researched for: Metabolic Health.
Safety Considerations
CJC-1295: Common: transient flushing/"head rush" within 5-10 minutes post-injection — hallmark of a potent injection, harmless and brief Self-reported: flu-like symptoms, headaches, irritability, anxiety, nausea, hives (mild and transient) Water retention and edema (dose-dependent; elevated GH causes sodium/water retention via kidneys)
SS-31: Generally well-tolerated in clinical trials at tested doses Common: injection site reactions (pain, redness) Mild headache, dizziness, and nausea reported
Related Products
Related Research News
CJC-1295 with DAC and Ipamorelin: Growth Hormone Research Guide
CJC-1295 with DAC and Ipamorelin represent key compounds in growth hormone research, targeting distinct pathways for GH and IGF-1 signaling. CJC-1295 with DAC acts as a long-acting GHRH analogue with a half-life of 5.8 to 8.1 days, while Ipamorelin functions as a selective growth hormone secretagogue via the ghrelin receptor. Together, they support studies on metabolism, recovery, and body composition.
CJC-1295 + Ipamorelin: Growth Hormone Stack Mechanics
CJC-1295 and Ipamorelin form the most studied growth hormone peptide combination in research. They target separate receptor pathways to boost GH secretion through the somatotropic axis. This stack produces amplified GH pulses, with preclinical data showing 3 to 5 times baseline levels versus 1.5 to 2 times alone.
Anti-Aging Peptides: Research Compounds for Metabolism, Muscle, and Tissue Health
Explore a curated selection of anti-aging research peptides including BPC-157, GHK-CU, KPV, MOTS-C, NAD+, Retatrutide, SS-31, TB-500, and others. These compounds are studied for their potential roles in metabolism support, muscle growth, weight loss, and skin, tissue, and bone health. Average purity across products is 99.77%.